The GMP for Anlon Healthcare IPO has only recently started and is currently in its early sessions. Since the trend is still developing, it is too soon to assess a clear direction. Our team updates the Grey Market Premium (GMP) on a daily basis to provide you with the most accurate insights. Stay connected with us for the latest Anlon Healthcare IPO GMP movements, daily performance, and the expected listing price.
Desclamer:The GMP prices shown here are only news related to the grey market. We do not trade/deal in grey market or subject to rates (sub2), nor do we recommend trading in grey market.
Anlon Healthcare IPO Quick Snapshot
- IPO Opening Date: 26 August 2025
IPO Closing Date: 29 August 2025
Issue Size: ₹121.03 Crore
Fresh Issue: 1.33 Crore Shares (Entire issue is Fresh)
Offer for Sale (OFS): Nil
IPO Price: ₹86 – ₹91 per Share
Lot Size: 164 Shares
Minimum Investment (Retail): ₹14,924
Listing Exchange: BSE & NSE
Tentative Listing Date: 3 September 2025
Market Cap (Estimated): ₹483.68 Crore (at upper price band)
GMP (As of July 29, 2025): ₹0 (No premium reported yet)
Expected Listing Price: ₹91 (based on GMP trend so far)
Expected Gain: 0% (No GMP movement yet)
Anlon Healthcare IPO GMP Trend
GMP Table
Real-time IPO Grey Market Premium tracking
📋 Daily Update Instructions:
- Enter admin key and enable admin mode
- Update today’s GMP data in the table
- Click “Save Changes” to download JSON backup
- Copy the new data from JSON file to your HTML code
- Upload the updated HTML file to your website
📄 Current Data (Copy this to your HTML file):
| GMP Date | IPO Price | GMP | Sub2 Sauda Rate | Estimated Listing Price | Estimated Profit* | Last Updated | Actions |
|---|
IPO grey market premium (GMP) IN (Q&A)
What is IPO Grey Market Premium (GMP)?
A: IPO Grey Market Premium (GMP) is the price at which shares of an upcoming IPO are unofficially traded in the grey market before their official listing on stock exchanges. It reflects investor sentiment and possible listing expectations.
Q2. How is GMP calculated?
A: GMP is calculated as the difference between the grey market price and the IPO issue price.
For example: If the IPO price is ₹100 and GMP is ₹30, the expected listing price is ₹130.
Read More
Is GMP a reliable indicator for IPO listing gains?
A: While GMP gives an early sense of demand, it is unofficial and not regulated. It may fluctuate based on market buzz, subscription status, and demand from HNIs or institutions. It is not a guaranteed predictor of listing price.
Q4. What does ‘Subject to Sauda’ mean in GMP terms?
A: ‘Subject to Sauda’ is a grey market term indicating how much a seller can earn if they are allotted IPO shares. For example, if ‘Retail Subject to’ is ₹1,000, it means buyers are willing to pay ₹1,000 per application for confirmed allotments.
Q5. Is trading in grey market legal in India?
A: No, grey market trading is unofficial and unregulated in India. It operates outside the purview of SEBI. Participating in it involves risks, and investors are advised to rely only on official channels.
Q6. Why does GMP change daily?
A: GMP fluctuates due to several factors:
- Overall IPO demand and subscription numbers
- Market sentiment and news flow
- HNI and institutional interest
- Global and domestic market conditions
Q7. Should investors consider GMP before applying for an IPO?
A: GMP can be a useful sentiment indicator but should not be the sole reason for investing. It is important to review company fundamentals, financials, valuation, and risk factors mentioned in the RHP (Red Herring Prospectus).
Anlon Healthcare IPO Date
| IPO Activity | Date |
|---|---|
| IPO Open Date | 26th Aug 2025 |
| IPO Close Date | 29th Aug 2025 |
| Basis of Allotment Finalisation Date | 1st Sep 2025 |
| Refunds Initiation | 2nd Sep 2025 |
| Credit of Shares to Demat Account | 2nd Sep 2025 |
| IPO Listing Date | 3rd Sep 2025 |
Disclaimer: This content is for informational purposes only and should not be considered financial advice. Always consult a qualified financial advisor before investing. All investments carry market risks. The author has no intention to participate in this IPO.